Results 141 to 150 of about 136,011 (340)

A phase 3 trial of bevacizumab in ovarian cancer.

New England Journal of Medicine, 2011
BACKGROUND Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease.
T. Perren, A. Swart, J. Pfisterer, J. Ledermann, E. Pujade-Lauraine, G. Kristensen, M. Carey, P. Beale, A. Cervantes, C. Kurzeder, A. du Bois, J. Sehouli, R. Kimmig, A. Stähle, F. Collinson, S. Essapen, C. Gourley, A. Lortholary, F. Selle, M. Mirza, A. Leminen, M. Plante, D. Stark, W. Qian, M. Parmar, A. Oza   +25 more
semanticscholar   +1 more source

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang   +10 more
wiley   +1 more source

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report

Thoracic Cancer, Volume 13, Issue 23, Page 3408-3411, December 2022., 2022
We present a case treated with “lenvatinib rechallenge” for advanced thymic carcinoma who was previously treated with lenvatinib followed by multiple cytotoxic agents. Shortly after lenvatinib rechallenge, rapid pleural and pericardial effusion reduction was observed. Our case might suggest lenvatinib rechallenge as a treatment option for patients with
Yuto Terashima, Taiki Hakozaki, Susumu Takeuchi, Yukio Hosomi   +3 more
wiley   +1 more source

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]

, 2018
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph, Donahue, Timothy, Hines, O Joe, Hoos, William, Isacoff, William H, Rahib, Lola, Reber, Howard A, Upfill-Brown, Alexander   +7 more
core   +1 more source

Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab

Thoracic Cancer, Volume 13, Issue 23, Page 3412-3414, December 2022., 2022
A case of a non–small‐cell lung cancer patient harboring epidermal growth factor receptor mutation with multiple brain metastasis experienced a new ischemic stroke after treatment with ramucirumab. Abstract Vascular endothelial growth factor (VEGF) inhibitors have been widely investigated in the last 10 years, with particular attention paid to their ...
Guo‐Yu Chen, Wen‐Chien Cheng, Chih‐Yen Tu   +2 more
wiley   +1 more source

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial [PDF]

, 2014
Background: Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data are lacking regarding their natural history, associated complications and infusion pump performance in patients with ...
A Surov, AA Martoni, C Araújo, C Twelves, D Fagnani, D Haller, DC McGee, DZ Xiang, E Chu, E Chu, E McKenna, E Van Cutsem, EA Poplin, EB Lamont, F Ng, G Perrocheau, H-J Schmoll, I Kriegel, J Cassidy, J Cassidy, J Kawamura, J Shen-Gunther, L Cavanna, L Garrison, LB Saltz, M Gann Jr, M Karthaus, M Verso, M W Saif, MM Beckers, N Barbetakis, N Starling, P Debourdeau, R Biffi, S Lee, T Cartwright, T Conroy, The Meta-Analysis Group In Cancer, W Saber, W Scheithauer, W Sun, Y Inaba   +41 more
core   +2 more sources

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

Clinical Cancer Research, 2020
Purpose: Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive ...
D. Reardon, A. Desjardins, J. Vredenburgh, D. O’Rourke, D. Tran, K. Fink, L. Nabors, Gordon Li, D. Bota, R. Lukas, L. Ashby, J. Duic, M. Mrugala, S. Cruickshank, L. Vitale, Yi He, Jennifer A Green, M. Yellin, C. Turner, T. Keler, T. Davis, J. Sampson, ReACT trial investigators   +22 more
semanticscholar   +1 more source

Bevacizumab in the treatment of ovarian cancer [PDF]

Biologics: Targets and Therapy, 2011
Despite advances in surgical cytoreduction and cytotoxic chemotherapy, ovarian cancer continues to be the leading cause of death in women with gynecologic malignancy. Our understanding of the treatment of ovarian cancer was revolutionized with the discovery of platinum- and taxane-based adjuvant chemotherapy regimens.
Eskander, Ramez N, Randall, Leslie M
openaire   +6 more sources

Advances in Cytosolic Delivery of Proteins: Approaches, Challenges, and Emerging Technologies

Chemistry &Biodiversity, EarlyView.
Proteins regulate almost all biological processes, and overcoming the protein's natural membrane inpermeability will provide a unique opportunity for intracellular targeting of related therapeutic proteins. Chemical modification of proteins and different types of delivery vectors can mediate intracellular transport of proteins, providing new ideas for ...
Wenyan Zhang, Huiling Liu, Bingdong Zhu, Wen Li, Xue Han, Jiaojiao Fu, Renjie Luo, Haiyan Wang, Jinxia Wang   +8 more
wiley   +1 more source

Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial

Thoracic Cancer, Volume 13, Issue 24, Page 3496-3503, December 2022., 2022
Patients with T790M‐negative EGFR‐mutant advanced NSCLC received anlotinib plus platinum‐based chemotherapy after resistance to first‐ or second‐generation EGFR TKIs. The maximum tolerated dose (MTD) of anlotinib was 12 mg, and the median PFS was 5.75 (95% CI: 4.37–7.52) months.
Juan Li, Yuke Tian, Min Zheng, Jun Ge, Jiliang Zhang, Dejun Kong, Mei Chen, Ping Yu   +7 more
wiley   +1 more source